Most Recent Annual Report
2017 Annual Report and Form 10K
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV). It is also developing SMNH product candidates, including STimulator of INterferon Genes agonist, an immunotherapeutic agent for the potential treatment of selected cancers. Spring Bank Pharmaceuticals, Inc. has strategic collaborations with Gilead Sciences, Inc. to conduct a Phase II trial examining the co-administration of inarigivir and tenofovir alafenamide in patients infected with HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.